Rosa Sapena

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

Sophie Park, Jean-François Hamel, Andréa Toma et al. · Journal of Clinical Oncology · 2017 · 97 citations · Full text

Hematological Malignancy, Erythropoiesis-stimulating Agents, Oncology +14

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

Valeria Santini, Jennifer Schemenau, Alessandro Levis et al. · Blood · 2013 · 77 citations · Full text

Trimetazidine Counteracts the Hepatic Injury Associated with Ischemia-Reperfusion by Preserving Mitochondrial Function

Aziz Elimadi, Abdellatif Settaf, Didier Morin et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 76 citations

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

Charikleia Kelaïdi, Sophie Park, Rosa Sapena et al. · Leukemia · 2013 · 71 citations

Hematological Malignancy, Thrombosis, Erythropoiesis-stimulating Agents +9

Attenuation of liver normothermic ischemia-reperfusion injury by preservation of mitochondrial functions with S-15176, a potent trimetazidine derivative11Abbreviations: ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; PTP, permeability transition pore; RCR, respiratory control ratio; ROS, reactive oxygen species; and ΔΨ, mitochondrial membrane potential.

Aziz Elimadi, Rosa Sapena, Abdellatif Settaf et al. · Biochemical Pharmacology · 2001 · 70 citations

Permeability Transition Pore, Hepatology, Mitochondrial Function +13